Evolocumab as treatment in lorlatinib-related hyperlipidemia

Anti-PCSK9 monoclonal antibodies have reduced the risk of cardiovascular events in patients with atheroesclerosis cardiovascular disease. However, its use has not been described in hyperlipidemia associated with lorlatinib, a third-generation ALK tyrosin kinasa inhibitor approved as treatment for AL...

Full description

Saved in:

Bibliographic Details
Published in:	Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis Vol. 35; no. 2; p. 88
Main Authors:	Pérez Alonso, Laura, Cervera Calero, Raquel, Campos Fernández de Sevilla, María Ángeles, Moreno Palanco, Miguel Ángel, Gómez Cerezo, Jorge Francisco
Format:	Journal Article
Language:	English
Published:	Spain 01-03-2023
Subjects:	Anaplastic Lymphoma Kinase Carcinoma, Non-Small-Cell Lung - chemically induced Humans Hyperlipidemias - chemically induced Hyperlipidemias - drug therapy Lactams, Macrocyclic - adverse effects Lung Neoplasms - chemically induced Protein Kinase Inhibitors - adverse effects Lorlatinib Cáncer de pulmón no microcítico Evolocumab Seguridad Non-small-cell lung cancer Therapy management Tratamiento Safety
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Anti-PCSK9 monoclonal antibodies have reduced the risk of cardiovascular events in patients with atheroesclerosis cardiovascular disease. However, its use has not been described in hyperlipidemia associated with lorlatinib, a third-generation ALK tyrosin kinasa inhibitor approved as treatment for ALK-positive non-small cell lung cancer.
ISSN:	1578-1879
DOI:	10.1016/j.arteri.2022.12.003